Suramin sodium salt is a polysulfonated naphthylurea that inhibits the binding of calmodulin to recognition sites on the ryanodine receptor-1 (IC50 = 4.9 μM), blocks G protein coupling to GPCRs, and non-selectively antagonizes P2 purinergic receptors(10-100 μM).
Suramin sodium salt/苏拉明钠 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Saos-2 cells
10 –25 µM
6 weeks
No telomere shortening was observed
AAPS J. 2015 Jan;17(1):268-76.
DU145 cells
300 µg/ml
10 minutes
To determine the effects of suramin on tyrosine phosphorylation in DU145 cells, it was found that suramin significantly increased the tyrosine phosphorylation of 75 and 135 kDa proteins.
J Clin Invest. 1992 Dec;90(6):2166-74.
LNCaP cells
300 µg/ml
10 minutes
To determine the effects of suramin on tyrosine phosphorylation in LNCaP cells, it was found that suramin significantly increased the tyrosine phosphorylation of 75 and 135 kDa proteins.
J Clin Invest. 1992 Dec;90(6):2166-74.
Lycopersicon peruvianum suspension-cultured cells
700 µM
10 minutes
Suramin inhibited the alkalinization of the medium induced by systemin, chitosan, and pmg elicitor.
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8862-7.
Monocytes
200 µM
2 days
Suramin reduced the expression of FcγRI, FcγRII, FcεRII, and FcαR on monocytes and impaired their phagocytic capacity.
Immunology. 1994 Apr;81(4):598-604.
Chinese hamster fibrosarcoma cells (DC-3F)
50 µM
24 hours
Determine the intracellular distribution of Suramin, results showed Suramin was predominantly located in the nucleus.
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3025-9.
KB cells
300 µM
24 hours and 48 hours
To investigate the effect of Suramin on the growth of KB cells, results showed that Suramin was able to sustain the growth of KB carcinoma cells cultured under serum-free conditions.
J Clin Invest. 1992 Apr;89(4):1242-7.
HEK293T cells
0.02 - 5 mM
4 hours
To evaluate the neutralizing effect of Suramin on SARS-CoV-2 pseudotyped viral particles, results showed that Suramin exhibited broad entry inhibition among all three variants tested (wild type, Delta, and Omicron)
Commun Biol. 2023 Apr 8;6(1):387.
Vero E6 cells
5, 10, 50, 100, 1000, 10000 µM
48 hours
To evaluate the cytotoxicity of Suramin on Vero E6 cells, results showed very low cytotoxicity (<20%) even at suramin concentrations up to 10 mM
Commun Biol. 2023 Apr 8;6(1):387.
Lycopersicon peruvianum suspension-cultured cells
1 mM
5 minutes
Suramin inhibited the activation of the 48-kDa MBP kinase induced by systemin, chitosan, and pmg elicitor.
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8862-7.
FaDu cells
10 –25 µM
6 weeks
Inhibited telomerase activity, leading to gradual telomere shortening (maximum of 30%) and cell senescence
AAPS J. 2015 Jan;17(1):268-76.
PC3 cells
10 –25 µM
6 weeks
Inhibited telomerase activity, leading to gradual telomere shortening (maximum of 30%) and cell senescence
AAPS J. 2015 Jan;17(1):268-76.
MCF7 cells
10 –25 µM
6 weeks
Inhibited telomerase activity, leading to gradual telomere shortening (maximum of 30%) and cell senescence
AAPS J. 2015 Jan;17(1):268-76.
A431 cells
100 µM and 300 µM
72 hours and 96 hours
To investigate the effect of Suramin on EGFR in A431 cells, results showed that Suramin treatment led to a dramatic reduction in EGFR abundance and a shift in EGFR mobility, indicating Suramin-induced downregulation of EGFR.
J Clin Invest. 1992 Apr;89(4):1242-7.
U937 cells
50-200 µM
8-72 hours
Suramin inhibited the proliferation of U937 cells and reduced the expression of FcγRI, FcγRII, FcεRII, and FcαR.
Immunology. 1994 Apr;81(4):598-604.
U-266 cells
30 µM
90 minutes
Suramin inhibited the binding of 125I-IL-6 to U-266 cells, with a half-maximal inhibition concentration of 30 μM
J Clin Invest. 1993 Nov;92(5):2152-9.
MCF-7 cells
300 µM
90 minutes
Suramin inhibited the binding of 125I-TNFα to MCF-7 cells, with a half-maximal inhibition concentration of 300 μM
J Clin Invest. 1993 Nov;92(5):2152-9.
PC3 cells
300 µg/ml
seconds
To determine the effects of suramin on tyrosine phosphorylation in PC3 cells, it was found that suramin significantly increased the tyrosine phosphorylation of several distinct proteins.
J Clin Invest. 1992 Dec;90(6):2166-74.
U2OS cells
62.5 to 500 µM
Suramin at 62.5 μM accumulated p27 and CDT1, and at 250-500 μM accumulated Nrf2, indicating that Suramin inhibits CRL-mediated ubiquitination, leading to the accumulation of CRL substrates.
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2011-8.
B-9 cells
30 µM
Suramin inhibited the proliferation of B-9 cells in response to IL-6, with a half-maximal inhibition concentration of 30 μM
J Clin Invest. 1993 Nov;92(5):2152-9.
Suramin sodium salt/苏拉明钠 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
FaDu tumor model
Intravenous injection
10 mg/kg
Twice a week for 6 weeks
Resulted in telomere shortening of >40% in tumor cells
AAPS J. 2015 Jan;17(1):268-76.
Mice
Pkd1-deficient mouse model
Intraperitoneal injection
60 mg/kg
Twice a week for 8 weeks
Suramin significantly reduced renal cyst densities, cell proliferation, and macrophage infiltration, but did not improve kidney function
Int J Mol Sci. 2022 Jul 31;23(15):8499
Tomato plants
14-day-old tomato plants
Supplied through cut stems
700 µM
1-hour pretreatment
Suramin inhibited the synthesis of serine proteinase inhibitors I and II induced by systemin and completely inhibited the synthesis of inhibitors induced by wounding.
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8862-7.
BALB/c X DBA/2 (CD)F1 mice
C-26 adenocarcinoma model
Intraperitoneal injection
75 mg/kg
Injected on days 7 and 12
Suramin significantly improved weight loss in C-26 adenocarcinoma model mice, reducing muscle and fat tissue wasting and hypoglycemia
United States, Maryland
... 展开 >>
National Institutes of Health Clinical Center, 9000 Rockville Pike
Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-441-1222 ext TTY8864111010 prpl@cc.nih.gov 收起 <<
Germany
... 展开 >> National Center for Tumor Diseases
Recruiting
Heidelberg, Germany, 69120
Contact: Joachim Wiskemann, Dr. joachim.wiskemann@nct-heidelberg.de
Contact: Jana Müller jana.mueller@nct-heidelberg.de 收起 <<
United States, Maryland
... 展开 >>
National Institutes of Health Clinical Center, 9000 Rockville Pike
Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-441-1222 ext TTY8864111010 prpl@cc.nih.gov 收起 <<
Germany
... 展开 >> National Center for Tumor Diseases
Recruiting
Heidelberg, Germany, 69120
Contact: Joachim Wiskemann, Dr. joachim.wiskemann@nct-heidelberg.de
Contact: Jana Müller jana.mueller@nct-heidelberg.de 收起 <<
Brain and Central Nervous Syst... 展开 >>em Tumors 收起 <<
Phase 2
Completed
-
United States, Alabama
... 展开 >>
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
United States, Georgia
Emory University Hospital - Atlanta
Atlanta, Georgia, United States, 30322
United States, Maryland
Johns Hopkins Oncology Center
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, North Carolina
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157-1082
United States, Pennsylvania
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78284-7811 收起 <<
Recurrent Non-small Cell Lung ... 展开 >>Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer 收起 <<
Phase 2
Completed
-
United States, Ohio
... 展开 >>
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States, 43210 收起 <<
United States, Wisconsin
... 展开 >>
University of Wisconsin Carbone Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792
Medical College of Wisconsin
Milwaukee, Wisconsin, United States 收起 <<
United States, Illinois
... 展开 >>
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States, 60612
United States, Virginia
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, United States, 23298 收起 <<
搜索
